Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trialPaolo A. Ascierto, Giuseppe Palmieri, Claudia Piccinini et al.|Nature Communications|2024Cited by 94
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaPaolo A. Ascierto, Vanna Chiarion‐Sileni, Mario Mandalà et al.|NEJM Evidence|2024Cited by 13